Skip to main content
Log in

Fecal Calprotectin Evaluation in Patients with Ulcerative Colitis

  • Correspondence
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Burri E, Beglinger C, von Felten S, Lehmann FS. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2014 (Epub ahead of print). doi:10.1007/s10620-014-3383-0

  2. Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol. 2008;155:1085–1092.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Yousefi A, Shafieyoun A, Fallahi G, Rezaei N. Probiotics on fecal calprotectin of cystic fibrosis. Turk J Pediatr. 2014;56:333.

    PubMed  Google Scholar 

  4. Zheng Y, Hou J, Peng L, et al. The pro-apoptotic and pro-inflammatory effects of calprotectin on human periodontal ligament cells. PLoS ONE. 2014;9:e110421.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Lasson A, Stotzer PO, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2014;. doi:10.1016/j.crohns.2014.06.002.

    Google Scholar 

  6. Cotoi OS, Duner P, Ko N, et al. Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler Thromb Vasc Biol. 2014;34:202–210.

    Article  CAS  PubMed  Google Scholar 

  7. Jost T, Lacroix C, Braegger C, Chassard C. Stability of the maternal gut microbiota during late pregnancy and early lactation. Curr Microbiol. 2014;68:419–427.

    Article  CAS  PubMed  Google Scholar 

  8. Agilli M, Aydin I, Aydin FN. Fecal calprotectin levels in patients with cystic fibrosis. Turk J Pediatr. 2014;56:332.

    PubMed  Google Scholar 

  9. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.

    Article  PubMed  Google Scholar 

  10. Crockett SD, Hansen RA, Sturmer T, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012;18:1048–1056.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–383.

    Article  CAS  PubMed  Google Scholar 

  12. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–487.

    PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tolga Dogan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dogan, T., Agilli, M. Fecal Calprotectin Evaluation in Patients with Ulcerative Colitis. Dig Dis Sci 60, 1109–1110 (2015). https://doi.org/10.1007/s10620-015-3527-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3527-x

Keywords

Navigation